Skip to main content
Top
Published in: BMC Gastroenterology 1/2018

Open Access 01-12-2018 | Study protocol

Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure

Authors: Marcus Hollenbach, Christiane Prettin, Felix Gundling, Wolfgang Schepp, Jochen Seufert, Jürgen Stein, Thomas Rösch, Jens Aberle, Jürgen Feisthammel, David Petroff, Albrecht Hoffmeister

Published in: BMC Gastroenterology | Issue 1/2018

Login to get access

Abstract

Background

Obesity is a global problem leading to reduced life expectancy, cardiovascular diseases, diabetes and many types of cancer. Even people willing to accept treatment only achieve a mean weight loss of about 5 kg using commercial weight loss programs. Surgical interventions, e.g. sleeve gastrectomy or gastric bypass are effective but accompanied by risk of serious complications and side effects. Less invasive endoscopic procedures mainly comprise the intragastric balloon (IB) and the duodenal-jejunal bypass liner (DJBL). To date, a randomized comparison between these devices has not been undertaken or shown to be superior to a sham procedure.

Methods

We designed a multi-center, randomized, patient and assessor-blinded, controlled trial comparing weight loss in endoscopically implanted IB vs. DJBL vs. a sham procedure. A total of 150 patients with a BMI > 35 kg/m2 or > 30 with obesity-related comorbidities and indication for proton pump inhibitors are randomized to receive either IB, DJBL or a sham gastroscopy (2:2:1 ratio). All participants undergo regular dietary consultation. The IB will be removed after 6 months, whereas the DJBL will be explanted after 12 months. All patients will receive gastroscopies at implantation and explantation of the devices or sedation without gastroscopy to maintain blinding. Main exclusion criteria are malignant diseases, peptic ulcer or previous bariatric intervention. Weight loss 12 months after explantation of the devices, changes in comorbidities, quality of life, complication rates and safety will be evaluated.

Discussion

This trial could help to identify the most effective and safest endoscopic device, thus determining the new standard procedure for endoscopic bariatric treatment.

Trial registration

16th January 2017. DRKS00011036. Funded by the German Research Foundation (DFG).
Literature
2.
go back to reference Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38.CrossRefPubMed Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38.CrossRefPubMed
3.
go back to reference Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American ASSOCIATION of clinical endocrinologists and AMERICAN COLLEGE of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.CrossRefPubMed Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American ASSOCIATION of clinical endocrinologists and AMERICAN COLLEGE of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.CrossRefPubMed
4.
go back to reference Jebb SA, Ahern AL, Olson AD, Aston LM, Holzapfel C, Stoll J, et al. Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial. Lancet. 2011;378(9801):1485–92.CrossRefPubMedPubMedCentral Jebb SA, Ahern AL, Olson AD, Aston LM, Holzapfel C, Stoll J, et al. Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial. Lancet. 2011;378(9801):1485–92.CrossRefPubMedPubMedCentral
5.
go back to reference Hammer HF. Medical complications of bariatric surgery: focus on malabsorption and dumping syndrome. Dig Dis. 2012;30(2):182–6.CrossRefPubMed Hammer HF. Medical complications of bariatric surgery: focus on malabsorption and dumping syndrome. Dig Dis. 2012;30(2):182–6.CrossRefPubMed
6.
go back to reference Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275–87.CrossRefPubMedPubMedCentral Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275–87.CrossRefPubMedPubMedCentral
7.
go back to reference Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology. 2017; Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology. 2017;
8.
go back to reference bu Dayyeh BK, Thompson CC. Obesity and bariatrics for the endoscopist: new techniques. Therap Adv Gastroenterol. 2011;4(6):433–42.CrossRef bu Dayyeh BK, Thompson CC. Obesity and bariatrics for the endoscopist: new techniques. Therap Adv Gastroenterol. 2011;4(6):433–42.CrossRef
9.
go back to reference Fanelli RD, Andrew BD. Is Endoluminal bariatric therapy a new paradigm of treatment for obesity? Clin Gastroenterol Hepatol. 2016;14(4):507–15.CrossRefPubMed Fanelli RD, Andrew BD. Is Endoluminal bariatric therapy a new paradigm of treatment for obesity? Clin Gastroenterol Hepatol. 2016;14(4):507–15.CrossRefPubMed
10.
go back to reference De WB, Reynaert H, Urbain D, Willems G. Intragastric balloons for preoperative weight reduction. Obes Surg. 2000;10(1):58–60.CrossRef De WB, Reynaert H, Urbain D, Willems G. Intragastric balloons for preoperative weight reduction. Obes Surg. 2000;10(1):58–60.CrossRef
11.
go back to reference bu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, Larsen M, Sullivan S, et al. ASGE bariatric endoscopy task force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38.CrossRef bu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, Larsen M, Sullivan S, et al. ASGE bariatric endoscopy task force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38.CrossRef
12.
go back to reference Genco A, Lopez-Nava G, Wahlen C, Maselli R, Cipriano M, Sanchez MM, et al. Multi-Centre European experience with intragastric balloon in overweight populations: 13 years of experience. Obes Surg. 2013;23(4):515–21.CrossRefPubMed Genco A, Lopez-Nava G, Wahlen C, Maselli R, Cipriano M, Sanchez MM, et al. Multi-Centre European experience with intragastric balloon in overweight populations: 13 years of experience. Obes Surg. 2013;23(4):515–21.CrossRefPubMed
13.
go back to reference Kotzampassi K, Grosomanidis V, Papakostas P, Penna S, Eleftheriadis E. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. 2012;22(6):896–903.CrossRefPubMed Kotzampassi K, Grosomanidis V, Papakostas P, Penna S, Eleftheriadis E. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. 2012;22(6):896–903.CrossRefPubMed
14.
go back to reference Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18(12):1611–7.CrossRefPubMed Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18(12):1611–7.CrossRefPubMed
15.
go back to reference Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61(1):19–27.CrossRefPubMed Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61(1):19–27.CrossRefPubMed
16.
go back to reference Martinez-Brocca MA, Belda O, Parejo J, Jimenez L, del VA, Pereira JL, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17(5):649–57.CrossRefPubMed Martinez-Brocca MA, Belda O, Parejo J, Jimenez L, del VA, Pereira JL, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17(5):649–57.CrossRefPubMed
17.
go back to reference Genco A, Cipriano M, Bacci V, Cuzzolaro M, Materia A, Raparelli L, et al. BioEnterics Intragastric balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30(1):129–33.CrossRef Genco A, Cipriano M, Bacci V, Cuzzolaro M, Materia A, Raparelli L, et al. BioEnterics Intragastric balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30(1):129–33.CrossRef
18.
go back to reference de Moura EG, Lopes GS, Martins BC, Orso IR, Coutinho AM, de Oliveira SL, et al. Effects of duodenal-Jejunal bypass liner (EndoBarrier (R)) on gastric emptying in obese and type 2 diabetic patients. Obes Surg. 2015;25(9):1618–25.CrossRefPubMed de Moura EG, Lopes GS, Martins BC, Orso IR, Coutinho AM, de Oliveira SL, et al. Effects of duodenal-Jejunal bypass liner (EndoBarrier (R)) on gastric emptying in obese and type 2 diabetic patients. Obes Surg. 2015;25(9):1618–25.CrossRefPubMed
19.
go back to reference Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM, et al. A multicenter, randomized efficacy study of the EndoBarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236–43.CrossRefPubMed Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM, et al. A multicenter, randomized efficacy study of the EndoBarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236–43.CrossRefPubMed
20.
go back to reference Gersin KS, Rothstein RI, Rosenthal RJ, Stefanidis D, Deal SE, Kuwada TS, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976–82.CrossRefPubMed Gersin KS, Rothstein RI, Rosenthal RJ, Stefanidis D, Deal SE, Kuwada TS, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976–82.CrossRefPubMed
21.
go back to reference Escalona A, Pimentel F, Sharp A, Becerra P, Slako M, Turiel D, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg. 2012;255(6):1080–5.CrossRefPubMed Escalona A, Pimentel F, Sharp A, Becerra P, Slako M, Turiel D, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg. 2012;255(6):1080–5.CrossRefPubMed
22.
go back to reference Koehestanie P, de JC, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–92.CrossRefPubMed Koehestanie P, de JC, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–92.CrossRefPubMed
23.
go back to reference Feisthammel J, Bluher M, Mossner J, Hoffmeister A. Endoscopic treatment of obesity and complications following bariatric surgery. Internist (Berl). 2016;57(8):748–54.CrossRef Feisthammel J, Bluher M, Mossner J, Hoffmeister A. Endoscopic treatment of obesity and complications following bariatric surgery. Internist (Berl). 2016;57(8):748–54.CrossRef
24.
go back to reference Petroff D, Hoffmeister A. Excess weight loss should not be used to define success for bariatric endoscopy. Gastrointest Endosc. 2016;83(6):1306.CrossRefPubMed Petroff D, Hoffmeister A. Excess weight loss should not be used to define success for bariatric endoscopy. Gastrointest Endosc. 2016;83(6):1306.CrossRefPubMed
25.
go back to reference Cohen RV, Neto MG, Correa JL, Sakai P, Martins B, Schiavon CA, et al. A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes. J Clin Endocrinol Metab. 2013;98(2):E279–82.CrossRefPubMed Cohen RV, Neto MG, Correa JL, Sakai P, Martins B, Schiavon CA, et al. A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes. J Clin Endocrinol Metab. 2013;98(2):E279–82.CrossRefPubMed
26.
go back to reference de JC, Rensen SS, Verdam FJ, Vincent RP, Bloom SR, Buurman WA, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg. 2013;23(9):1354–60.CrossRef de JC, Rensen SS, Verdam FJ, Vincent RP, Bloom SR, Buurman WA, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg. 2013;23(9):1354–60.CrossRef
27.
go back to reference Koehestanie P, Dogan K, Berends F, Janssen I, Wahab P, Groenen M, et al. Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, accompanied by elevated fasting ghrelin levels. Endosc Int Open. 2014;2(1):E21–7.CrossRefPubMedPubMedCentral Koehestanie P, Dogan K, Berends F, Janssen I, Wahab P, Groenen M, et al. Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, accompanied by elevated fasting ghrelin levels. Endosc Int Open. 2014;2(1):E21–7.CrossRefPubMedPubMedCentral
28.
go back to reference Munoz R, Escalona A. Duodenal-jejunal bypass liner to treat type 2 diabetes mellitus in morbidly obese patients. Curr Cardiol Rep. 2014;16(3):454.CrossRefPubMed Munoz R, Escalona A. Duodenal-jejunal bypass liner to treat type 2 diabetes mellitus in morbidly obese patients. Curr Cardiol Rep. 2014;16(3):454.CrossRefPubMed
29.
go back to reference Munoz R, Dominguez A, Munoz F, Munoz C, Slako M, Turiel D, et al. Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients. Surg Endosc. 2014;28(4):1056–62.CrossRefPubMed Munoz R, Dominguez A, Munoz F, Munoz C, Slako M, Turiel D, et al. Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients. Surg Endosc. 2014;28(4):1056–62.CrossRefPubMed
30.
go back to reference Vilarrasa N. EndoBarrier(R) in grade I obese patients with long-standing type 2 diabetes: role of gastrointestinal hormones in glucose metabolism. Obes Surg. 2017;27(1):194–5.CrossRefPubMed Vilarrasa N. EndoBarrier(R) in grade I obese patients with long-standing type 2 diabetes: role of gastrointestinal hormones in glucose metabolism. Obes Surg. 2017;27(1):194–5.CrossRefPubMed
31.
go back to reference de JC, Rensen SS, Koek GH, Joosten MF, Buurman WA, Bouvy ND, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11(11):1517–20.CrossRef de JC, Rensen SS, Koek GH, Joosten MF, Buurman WA, Bouvy ND, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11(11):1517–20.CrossRef
32.
go back to reference Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50.CrossRefPubMed Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50.CrossRefPubMed
33.
go back to reference Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and Management of Obesity. N Engl J Med. 2017;376(3):254–66.CrossRefPubMed Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and Management of Obesity. N Engl J Med. 2017;376(3):254–66.CrossRefPubMed
Metadata
Title
Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure
Authors
Marcus Hollenbach
Christiane Prettin
Felix Gundling
Wolfgang Schepp
Jochen Seufert
Jürgen Stein
Thomas Rösch
Jens Aberle
Jürgen Feisthammel
David Petroff
Albrecht Hoffmeister
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2018
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-018-0838-3

Other articles of this Issue 1/2018

BMC Gastroenterology 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.